LifeScan has announced a strategic partnership with global biosensor manufacturer i-SENS to launch a new continuous glucose monitoring (CGM) system under its OneTouch® Vita brand, marking a significant expansion into the fast-growing CGM segment.
The Malvern, Pennsylvania-based company said it expects to introduce the new CGM products in Germany, Ireland, Portugal and Belgium by early 2027, with plans to roll out in additional markets over time.
The move represents a major step in LifeScan’s evolution as it broadens its presence beyond traditional blood glucose monitoring systems. The partnership combines LifeScan’s established OneTouch®️ brand and global commercial infrastructure with i-SENS’ biosensor technology and manufacturing capabilities.
LifeScan, which has operated in the diabetes care sector for more than four decades, said the addition of CGM technology aligns with its long-term strategy to expand innovation and enhance quality of life for people living with diabetes. The company confirmed that the rest of the OneTouch®️ portfolio will remain unchanged following the announcement.
By entering the CGM market, LifeScan strengthens its competitive position in glucose management, a sector that has increasingly shifted toward real-time, sensor-based monitoring solutions. The collaboration with i-SENS is expected to accelerate the development and commercialization of the new product line in Europe before broader international expansion.
